Research & Education

IASLC Supports the CMS Formal Proposal to Pay For Lung Cancer Screening

DENVER – The International Association for the Study of Lung Cancer (IASLC) is pleased that the Centers for Medicare & Medicaid Services (CMS) made a draft proposal Monday to cover low-dose CT screening of patients at high risk for lung cancer.

Interstitial lung disease is a significant risk factor for lung inflammation following stereotactic body radiation therapy for lung cancer.

DENVER – Pretreatment interstitial lung disease (ILD) is a significant risk factor for developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT) alone.

Risk stratification model may aid in lung cancer staging and treatment decisions.

DENVER – A risk stratification model based on lymph node characteristics confirms with a high level of confidence the true lack of lung cancer in lymph nodes adequately sampled with endobronchial ultrasound-guided transbronchial needle aspiration and classified as negative.

Prognostic factors identified for peripheral squamous cell carcinomas of the lung.

DENVER – A better survival outcome is associated with low blood levels of squamous cell carcinoma antigen, or absence of tumor invasion either into the space between the lungs and chest wall or into blood vessels of individuals with a peripheral squamous cell carcinoma, a type of non-small cell lung cancer (NSCLC).

Novel software application can stratify early-stage non-small cell lung cancer patients into risk categories based on analysis of computed tomography images.

DENVER –CANARY, Computer-Aided Nodule Assessment and Risk Yield, is a novel software tool developed at Mayo Clinic that can automatically quantitate adenocarcinoma pulmonary nodule characteristics from non-invasive high resolution computed tomography (HRCT) images and stratify non-small cell lung cancer (NSCLC) patients into risk groups that have significantly different disease-free survival outcome

European multicenter harmonization study shows anaplastic lymphoma kinase immunohistochemistry testing comparable to, if not better than, fluorescence in situ hybridization testing.

DENVER – Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase (ALK) protein expression test, immunohistochemistry (IHC), is reliable amongst several laboratories and review

Pages